Chief Financial Officer · Karyopharm Therapeutics Inc. (KPTI)

Michael Mason

A named executive officer of Karyopharm Therapeutics in every fiscal year CompBrief holds from FY2019 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$1,139,312

Salary $500,320Stock awards $426,632

FY2022: $2,699,032

4th of 5 named executive officers at Karyopharm Therapeutics by FY2023 total.

5 named officers on file for Karyopharm Therapeutics, FY2023

Michael Mason’s pay file — $29

  • 5 fiscal years of pay, line by line
  • 2 equity grants, each cited to its filing
  • KPTI’s disclosed peer group of 1 company

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Karyopharm Therapeutics’s whole pay program stands against its peers

  • Karyopharm Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on KPTI→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 19, 2024 (DEF 14A).

Free

Get Michael Mason’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Michael Mason compensation by year

Karyopharm Therapeutics Summary Compensation Table · all 5 fiscal years held
In US dollars, as Karyopharm Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2019FY2020FY2021FY2022FY2023
Salary$340,332$415,624$444,386$472,000$500,320
Bonus$0$0$50,000$0$0
Stock awards$0$586,963$370,834$1,062,906$426,632
Option awards$529,935$1,096,226$681,352$954,532$0
Non-equity incentive$75,000$156,123$182,000$193,048$191,623
Pension and deferred compensation$0$0$0$0$0
All other$11,430$11,880$16,006$16,546$20,737
Total$956,697$2,266,816$1,744,578$2,699,032$1,139,312

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Karyopharm Therapeutics Inc. DEF 14A filed April 19, 2024, accession 0000950170-24-045717, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Karyopharm Therapeutics Inc. filed document, accession 0000950170-24-045717. Every figure is read from that document and cited to the page and table it appears in. Filed April 19, 2024.

$957K
$2.3M
$1.7M
$2.7M
$1.1M
FY19
FY20
FY21
FY22
FY23
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
RSU66,150$57,551—
RSU11,006$9,575—
RSU8,150$7,091—
RSU2,750$2,393—
Option60,450—$10.33
Option15,000—$5.06
Option3,650—$18.00
Option17,491—$14.56
Option5,625—$9.15

Per the Outstanding Equity Awards at Fiscal Year-End table in Karyopharm Therapeutics Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Karyopharm Therapeutics’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Richard PaulsonPresident and Chief Executive Officer$2,626,288
Reshma RangwalaChief Medical Officer and Head of Research$1,227,789
Sohanya ChengExecutive Vice President, Chief Commercial Officer and Head of Business Development$1,193,414
Michael Mason · this pageChief Financial Officer$1,139,312
Stuart PoultonChief Development Officer$1,109,115

The full Karyopharm Therapeutics compensation record

free company brief

This page is one person within Karyopharm Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Karyopharm Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Karyopharm Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Michael Mason's compensation dossier · One-time report. No refunds.